

Sychev Dmitry

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4548256/sychev-dmitry-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

175
papers

443
citations

9
h-index

13
g-index

209
ext. papers

554
ext. citations

1
avg, IF

3.85
L-index

#	Paper	IF	Citations
175	Efficiency of treatment of laryngopharyngeal reflux with proton pump inhibitors depending on the CYP2C19 polymorphism. <i>Medsitsinskiy Sovet</i> , 2022 , 35-43	0.4	
174	Drug-Induced Atrial Fibrillation / Atrial Flutter. <i>Rational Pharmacotherapy in Cardiology</i> , 2022 , 17, 1-18	0.5	
173	Pharmacogenetics of antiviral agents for the treatment of COVID-19. <i>Farmakogenetika I Farmakogenomika</i> , 2022 , 38-41	0.2	1
172	Importance of using a pharmacogenetic approach to predict individual pharmacokinetics and safety profile of apixaban. <i>Farmakogenetika I Farmakogenomika</i> , 2022 , 4-8	0.2	
171	Influence of the NAT2 gene polymorphic markers on the effectiveness and safety of treatment in patients with newly diagnosed pulmonary tuberculosis based on peripheral red blood cell dynamics. <i>Antibiotiki I Khimioterapiya</i> , 2022 , 66, 30-38	0.4	
170	CYP2D6 gene polymorphic markers role in determining the optimal treatment tactics for portal hypertension in patients with liver cirrhosis. <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 200-208	0.9	1
169	Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2. <i>Sovremennaya Revmatologiya</i> , 2022 , 16, 60-67	0.7	1
168	Consensus expert opinion on key items in planning and designing clinical trials in geriatric patients. <i>Russian Journal of Geriatric Medicine</i> , 2022 , 398-402	2	
167	Genetic Risk Factors for Adverse Drug Reactions. <i>Safety and Risk of Pharmacotherapy</i> , 2022 , 10, 48-64	1.2	0
166	The Impact of Medication Reconciliation on Continuity of Drug Therapy during Perioperative Period. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2022 , 77, 53-61	0.4	
165	Drug-induced hypertension. <i>Medical Alphabet</i> , 2022 , 8-13	0.3	
164	CYP2D6 gene polymorphism effect on central hemodynamic parameters in patients with portal hypertension taking propranolol. <i>Medsitsinskiy Sovet</i> , 2022 , 83-91	0.4	
163	Drug-induced pulmonary artery hypertension. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2022 , 53-63	0.4	1
162	Pages from the history of therapeutic schools of the Central Institute for Improvement of Doctors [Russian Medical Academy of Continuous Professional Education. <i>Terapevticheskii Arkhiv</i> , 2022 , 94, 596-599	0.9	1
161	CYP2C8, PTGS-1, 2 gene polymorphisms prevalence associated with sensitivity to non-steroidal anti-inflammatory drugs among North Caucasus ethnic groups. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 1334-1339	0.9	
160	Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. <i>Psychopharmacology Bulletin</i> , 2021 , 51, 69-80	0.9	
159	Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. <i>Psychopharmacology Bulletin</i> , 2021 , 51, 31-42	0.9	

158	MicroRNAs as Novel Biomarkers for P2Y12 - Inhibitors Resistance Prediction. <i>Pharmacogenomics and Personalized Medicine</i> , 2021 , 14, 1575-1582	2.1	1
157	Study of the Effect of Polymorphic Markers of the NAT2 Gene on the Risk of Adverse Drug Reactions in Patients with Pulmonary Tuberculosis Who Received Isoniazid and Rifampicin. <i>Safety and Risk of Pharmacotherapy</i> , 2021 , 9, 25-33	1.2	2
156	Advanced Age as a Risk Factor of Drug-Induced Diseases. <i>Safety and Risk of Pharmacotherapy</i> , 2021 , 9, 15-24	1.2	3
155	Effect of polymorphisms in CYP3A4*22 (rs35599367) C>T, CYP3A5*3 (rs776746) A>G, ABCB1 (rs4148738) C>T and ABCB1 (rs1045642) C>T genes on apixaban anticoagulation: pilot study results. <i>Meditsinskiy Sovet</i> , 2021 , 41-46	0.4	
154	Aspects of practical application of STOPP/START criteria in elderly patients with atrial fibrillation and chronic kidney disease in therapeutic department of multi-speciality hospital. <i>Medical Alphabet</i> , 2021 , 57-65	0.3	
153	Efficiency and safety of pharmacotherapy for postoperative pain in cardiac surgery. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2021 , 20, 2683	0.9	0
152	The Continuity of Chronic Medications in Multimorbid Patients during Perioperative Period: Retrospective Analysis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021 , 76, 210-220	0.4	
151	Some groups of drugs which use is associated with development of drug-induced atrial fibrillation. <i>Medical Alphabet</i> , 2021 , 1, 20-28	0.3	1
150	The effect of and gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy. <i>Drug Metabolism and Personalized Therapy</i> , 2021 ,	2	2
149	Female Gender as a Risk Factor for the Development of Drug-Induced Diseases. <i>Safety and Risk of Pharmacotherapy</i> , 2021 , 9, 85-94	1.2	1
148	Supporting frontline clinicians in the time of the pandemic: Rapid response pharmacology team. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 725-729	3.8	1
147	Polymorphism 3435c> t of the ABCB1 gene (rs1045642) does not affect the mirtazapine efficiency and safety profile in patients with depressive disorders comorbid with alcohol use disorder. <i>Bulletin of Siberian Medicine</i> , 2021 , 19, 73-79	0.4	
146	Comparative analysis of N-acetyltransferase 2 genotyping results among patients with newly diagnosed pulmonary tuberculosis residing in the Sakha Republic (Yakutia). <i>Bulletin of Siberian Medicine</i> , 2021 , 19, 102-109	0.4	
145	Olanzapine-Associated Rhabdomyolysis: A Case Report. <i>Cureus</i> , 2021 , 13, e12568	1.2	0
144	Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. <i>Pharmacogenomics Journal</i> , 2021 , 21, 435-439	3.5	0
143	Analysis of the composition of hospitalized patients with the new coronavirus infection COVID-19. <i>Zdravookhranenie Rossiiskoi Federatsii / Ministerstvo Zdravookhraneniia RSFSR</i> , 2021 , 65, 183-190	0.3	1
142	Analysis of associations between pharmacodynamic genetic factors and antipsychotics effectiveness and safety in adolescents with acute psychotic episodes taking antipsychotics during a 28-day follow-up. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 78-88	0.4	
141	Alcohol as a risk factor for drug-induced diseases. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 52-66	0.4	

140	Drugs associated with drug-induced interstitial lung diseases. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 39-51	0.4	
139	Changes in anticoagulant prescription in a general hospital in 2008-2018. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 544-551	0.5	
138	Evaluation of the Influence of CYP2C9* 2, CYP2C9*3 Gene Polymorphisms on the Efficacy and Safety of Postoperative Analgesia with Ketoprofen in Patients after Cardiac Surgery. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 570-575	0.5	3
137	Methotrexate Safety in Psoriasis: An Overview. <i>Vestnik Rossijskoi Akademii Meditsinskikh Nauk</i> , 2021 , 76, 254-267	0.4	
136	Pharmacogenetic approach to methotrexate-related toxicity prediction in psoriasis. <i>Russian Journal of Skin and Venereal Diseases</i> , 2021 , 24, 119-132	0.1	
135	Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. <i>Psychopharmacology Bulletin</i> , 2021 , 51, 87-104	0.9	
134	Antibiotic therapy under polypragmatic conditions: a course to safety. <i>Klinicheskaa Mikrobiologia I Antimikrobnaa Himioterapia</i> , 2021 , 23, 367-373	1.3	1
133	Antibiotic therapy under polypragmatic conditions: a course to safety. <i>Klinicheskaa Mikrobiologia I Antimikrobnaa Himioterapia</i> , 2021 , 23, 367-373	1.3	
132	The effect of and gene polymorphisms on the efficacy and safety of the combination of tramadol and ketorolac used for postoperative pain management in patients after video laparoscopic cholecystectomy.. <i>Drug Metabolism and Personalized Therapy</i> , 2021 , 37, 27-34	2	
131	CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes.. <i>Drug Metabolism and Personalized Therapy</i> , 2021 , 37, 47-53	2	
130	MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring.. <i>Drug Metabolism and Personalized Therapy</i> , 2021 , 37, 41-46	2	0
129	Meta-analysis of pharmacogenetic decision support systems used in psychiatry. <i>Vestnik Nevrologii, Psihiatrii I Nejrohirurgii</i> , 2021 , 860-869	0.1	
128	Drug-induced diarrhea associated with antineoplastic drugs. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021 , 13, 5-18	0.2	
127	Information technologies role in optimizing the application of drugs in clinical practice: a view of a clinical pharmacologist. <i>Ro-Rossijskij Ūrnal Terapevtičskoj Praktiki</i> , 2021 , 2, 30-32	0.1	
126	Associations of CYP2D6, ABCB1 2677G>T/A and 3435C>T with effectiveness and safety of pharmacotherapy for acute psychotic episodes in adolescents over 28 days. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2021 , 39-49	0.4	
125	CYP3A subfamily activity affects the equilibrium concentration of Phenazepam in patients with anxiety disorders and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020 , 21, 449-457	2.6	1
124	Interethnic differences in the prevalence of main cardiovascular pharmacogenetic biomarkers. <i>Pharmacogenomics</i> , 2020 , 21, 677-694	2.6	4
123	How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?. <i>Drug Metabolism and Personalized Therapy</i> , 2020 , 35,	2	6

122	May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban. <i>Pharmacogenomics and Personalized Medicine</i> , 2020 , 13, 29-37	2.1	4
121	Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder. <i>Gene</i> , 2020 , 739, 144513	3.8	6
120	Effects of polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder. <i>Pharmacogenomics</i> , 2020 , 21, 111-123	2.6	3
119	The polymorphic variants DRD2 rs1800497 and ABCB1 3435C>T are associated with antipsychotic safety parameters in adolescents with an acute psychotic episode: the results of a pilot study. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2020 , 12, 24-31	0.7	3
118	Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2020 ,	2	3
117	The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome. <i>Bulletin of Siberian Medicine</i> , 2020 , 18, 119-126	0.4	
116	Implementation of clinical decision support system for anticoagulant prescribing for patients with deep vein thrombosis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2020 , 75, 69-76	0.4	1
115	The Effect of Polymorphisms in the CYP2D6 and CYP2C9 Genes on the Clinical Efficacy of Tramadol and Ketorolac When Using the Accelerated Recovery Protocol in Patients With Uncomplicated Acute Calculous Cholecystitis Who Underwent Cholecystectomy. <i>Sklifosovsky Journal Emergency Medical Care</i> , 2020 , 9, 331-333	0.5	
114	Rationale for use mefloquine for COVID-19 treatment. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 103-105	0.4	
113	Current and future use of favipiravir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 106-114	0.4	1
112	Possibility to use barycytinib in patients with COVID-19, including for treatment of "cytokine storm". <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 11-14	0.4	1
111	Monitoring of safety using favipiravir: risk management of adverse drug reactions in clinical practice. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 115-119	0.4	2
110	Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 18-22	0.4	1
109	Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 23-27	0.4	1
108	Current and future use of angiotensin II receptor blockers in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 28-31	0.4	
107	Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19?. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 32-34	0.4	
106	Possibilities for the use of tofacitinib in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 35-38	0.4	
105	Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for "cytokine storm" therapy. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 4-7	0.4	

104	What are the indications for combined use of hydroxychloroquine and lopinavir/ritonavir, and how should treatment safety monitoring be performed?. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 47-49</i>	0.4	1
103	Could canakinumab be used for COVID-19?. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 50-52</i>	0.4	
102	Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 53-59</i>	0.4	
101	Possibilities for the use of anakinra in COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 60-63</i>	0.4	
100	Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 64-67</i>	0.4	
99	Rationality of routine clinical use of olokizumab in COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 68-70</i>	0.4	3
98	Current and future use of colchicine in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 71-74</i>	0.4	2
97	Current and future use of umifenovir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 75-80</i>	0.4	1
96	Possibility for the use of bromhexine to prevent infection with SARS-CoV-2. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 8-10</i>	0.4	
95	Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 81-86</i>	0.4	
94	Current and future use of vitamin D3 in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 87-89</i>	0.4	
93	Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 90-91</i>	0.4	
92	Current and future use of dipyridamole in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 92-95</i>	0.4	1
91	Dexamethasone use in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 96-98</i>	0.4	
90	Current and future use of remdesivir in patients with COVID-19. <i>Kachestvennaya Klinicheskaya Praktika, 2020, 99-102</i>	0.4	
89	Using a pharmacogenetic clinical decision support system to improve psychopharmacotherapy dosing in patients with affective disorders. <i>Drug Metabolism and Personalized Therapy, 2020, 35,</i>	2	1
88	Anaphylaxis and vitamin D: associations and perspectives. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii, 2020, 65, 31-36</i>	0.4	
87	Influence of the Acetylation Type on the Incidence of Isoniazid-Induced Hepatotoxicity in Patients with Newly Diagnosed Pulmonary Tuberculosis. <i>Antibiotiki I Khimioterapiya, 2020, 65, 31-36</i>	0.4	

86	Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 39-46	0.4	
85	Drug-induced atrial fibrillation associated with admission of cardiovascular medications. <i>Siberian Medical Review</i> , 2020 , 5-13	1.5	2
84	Atrial Fibrillation Associated with Anticancer Drugs. <i>Safety and Risk of Pharmacotherapy</i> , 2020 , 8, 178-190.	0.2	4
83	Is it possible to use riamilovir to prevent infection and treat COVID-19?. <i>Kachestvennaya Klinicheskaya Praktika</i> , 2020 , 15-17	0.4	0
82	Prevalence of polymorphisms in N-acetyltransferase 2 gene among patients of Yakut ethnicity newly diagnosed with pulmonary tuberculosis. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2020 , 75, 154-161	0.4	1
81	MicroRNA and vascular pathology of the eye. <i>Bulletin of Russian State Medical University</i> , 2020 , 5-9	0.4	
80	Pharmacogenetics of antipsychotics in adolescents with acute psychotic episode during first 14 days after admission: effectiveness and safety evaluation. <i>Drug Metabolism and Personalized Therapy</i> , 2020 , 35,	2	3
79	Problems of integrating medical science, image and practical health care: focus on personalized medicine. <i>Farmakogenetika I Farmakogenomika</i> , 2020 , 3-10	0.2	
78	Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects. <i>Meditsinskiy Sovet</i> , 2020 , 65-73	0.4	
77	Clinically relevant pharmacogenetic markers in Tatars and Balkars. <i>Molecular Biology Reports</i> , 2020 , 47, 3377-3387	2.8	2
76	Vitamin D and chronic spontaneous urticaria: searching for algorithms of personalized therapy. <i>Russian Journal of Allergy</i> , 2020 , 17, 95-101	0.2	
75	SPEECH AND MENTAL DEVELOPMENT IN CHILDREN WITH CEREBRAL PALSY. <i>Zabajkalskij Medicinskij Vestnik</i> , 2020 , 18-24	0.1	
74	Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2020 , 35,	2	1
73	Effects of the rs2244613 polymorphism of the CES1 gene on the antiplatelet effect of the receptor P2Y12 blocker clopidogrel. <i>Drug Metabolism and Personalized Therapy</i> , 2019 , 34,	2	2
72	An improved extraction protocol for therapeutic dabigatran monitoring using HPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019 , 1130-1131, 121808	3.2	4
71	Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder. <i>Canadian Journal of Physiology and Pharmacology</i> , 2019 , 97, 781-785	2.4	14
70	Genotyping and phenotyping CYP3A4/CYP3A5: no association with antiplatelet effect of clopidogrel. <i>Molecular Biology Reports</i> , 2019 , 46, 4195-4199	2.8	3
69	Genetic determinants of dabigatran safety (CES1 gene rs2244613 polymorphism) in the Russian population: multi-ethnic analysis. <i>Molecular Biology Reports</i> , 2019 , 46, 2761-2769	2.8	3

68	Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population. <i>Rational Pharmacotherapy in Cardiology</i> , 2019 , 15, 393-406 ^{0.5}	8	8
67	ADME pharmacogenetics: future outlook for Russia. <i>Pharmacogenomics</i> , 2019 , 20, 847-865	2.6	8
66	Pharmacogenetics of alcohol addiction: current perspectives. <i>The Application of Clinical Genetics</i> , 2019 , 12, 131-140	3.1	9
65	Effect of CYP3A4, CYP3A5, ABCB1 Gene Polymorphisms on Rivaroxaban Pharmacokinetics in Patients Undergoing Total Hip and Knee Replacement Surgery. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019 , 26, 413-420	2.9	7
64	Clinical pharmacology technologies for personalization of cardiovascular diseases drug treatment: focus on direct oral anticoagulants. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 299-306	0.4	1
63	The effect of anticholinergic medications on cognitive function of patients 80 years and older with essential hypertension. <i>Arterial Hypertension (Russian Federation)</i> , 2019 , 25, 246-257	0.7	4
62	Tapering (deprescribing) of benzodiazepine tranquilizers. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2019 , 11, 89-95	0.7	1
61	Falls in elderly patients with comorbidity, which were prescribed combined application of psychotropic and cardiovascular medicines. <i>Nervno-Myshechnye Bolezni</i> , 2019 , 9, 67-74	0.2	2
60	Association of CYP3A5 (6986A>G) gene polymorphism with the effectiveness of anti-inflammatory therapy in children with bronchial asthma. <i>Rossiyskiy Vestnik Perinatologii I Pediatrii</i> , 2019 , 64, 73-77	0.4	
59	The Effect of Cyp2d6 Gene Polymorphism on the Efficacy and Safety of Mirtazapine in Patients with Depressive Disorders Comorbid with Alcohol. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2019 , 74, 185-191	0.4	
58	Antihypertensive Effect Of Amlodipine In Co-Administration With Omeprazole In Patients With Hypertension And Acid-Related Disorders: Cytochrome P450-Associated Aspects. <i>Pharmacogenomics and Personalized Medicine</i> , 2019 , 12, 329-339	2.1	2
57	Comparison of Quantitative Analytical Techniques for Dabigatran in Blood Plasma of Humans with Knee Replacements. <i>Pharmaceutical Chemistry Journal</i> , 2019 , 53, 771-774	0.9	
56	The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 1-5	2.1	7
55	CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. <i>Genetic Testing and Molecular Biomarkers</i> , 2018 , 22, 51-54	1.6	6
54	CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 107-112	2.1	3
53	Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 113-119	2.1	11
52	The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 109-118 ²		4
51	Pharmacogenetic testing by polymorphic markers 681G>A and 636G>A CYP2C19 gene in patients with acute coronary syndrome and gastric ulcer in the Republic of Sakha (Yakutia). <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 91-98	2	5

50	FREQUENCY OF CYP2C19 AND ABCB1 GENES POLYMORPHISMS, ASSOCIATED WITH THE CHANGE, CAUSED BY CLOPIDOGREL ANTIAGREGANT AMONG THE RUSSIANS AND THE BURYATS. <i>Siberian Medical Review</i> , 2018 , 43-50	1.5	3
49	Potential of the Transdermal Drug Delivery Systems for the Topical Treatment of Chronic Venous Diseases. <i>Flebologiya</i> , 2018 , 12, 40	0.4	5
48	Risk of postoperative venous thromboembolic complication development in elderly patients. <i>Bulletin of Siberian Medicine</i> , 2018 , 17, 85-93	0.4	2
47	Current methods of optimization of pharmacotherapy in elderly patients in multidisciplinary hospital.. <i>Klinicheskaja Meditsina</i> , 2018 , 95, 1042-1049	0.2	
46	IMPACT OF CYP3A5, CYP2C9, CYP2C19, AND CYP2D6 POLYMORPHISMS ON PHENAZEPAM SAFETY IN PATIENTS WITH ALCOHOL WITHDRAWAL SYNDROME. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018 , 73, 206-214	0.4	1
45	Falls in the stationary for patients with cardiovascular diseases of the senior age and polypharmacy. <i>Nervno-Myshechnye Bolezni</i> , 2018 , 8, 19-27	0.2	3
44	Personalisation of antiplatelet therapy and secondary prevention of ischemic stroke.. <i>Klinicheskaja Meditsina</i> , 2018 , 96, 677-687	0.2	
43	Influence of CYP3A Activity on the Efficacy and Safety of Fluvoxamine in Patients Depressive Disorders and Comorbid Alcohol Use Disorder. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2018 , 73, 411-419	0.4	1
42	Evaluation of the rivaroxaban-influenced effect of ABCB1 and CYP3A5 gene polymorphisms on prothrombin time in patients after total hip or knee replacement surgery. <i>Bulletin of Russian State Medical University</i> , 2018 , 105-109	0.4	0
41	PHARMACOGENETIC STUDIES IN CARDIOLOGY: THE PROBLEM OF "DEPTH" OF THE ISSUE STUDY AND THE CORRECTNESS OF USING "GENETIC" TERMS. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 137-139	0.5	
40	Effects of polymorphisms on the efficacy and safety of amlodipine therapy in Caucasian patients with stage I-II hypertension. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 157-165	2.1	5
39	Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 699-702	0.5	1
38	Using a personalized clinical decision support system for bromdihydrochlorophenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers. <i>Human Psychopharmacology</i> , 2018 , 33, e2677	2.3	13
37	Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking β blockers in the Republic of Sakha (YAKUTIA). <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 195-200	2	5
36	Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder. <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 187-194	2	5
35	Physician Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 501-508	0.5	2
34	The Development of New Factor Xa Inhibitors Based on Amide Synthesis. <i>Current Drug Discovery Technologies</i> , 2018 , 15, 335-350	1.5	3
33	Influence of and gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 43-49	2.1	18

32	NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME. <i>Rational Pharmacotherapy in Cardiology</i> , 2018 , 14, 47-52	0.5	
31	Which cytochrome P450 metabolizes phenazepam? Step by step in silico, in vitro, and in vivo studies. <i>Drug Metabolism and Personalized Therapy</i> , 2018 , 33, 65-73	2	8
30	Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients. <i>Drug Metabolism and Personalized Therapy</i> , 2017 , 32, 109-114	2	2
29	Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. <i>Genetic Testing and Molecular Biomarkers</i> , 2017 , 21, 747-753	1.6	13
28	Comparison of , , , and gene-polymorphism frequency in Russian and Nanai populations. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 93-99	2.1	8
27	polymorphism frequency in Russian patients in Central Russia and Siberia with acute coronary syndrome. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 107-114	2.1	9
26	FROM PERSONALIZED TO PRECISION MEDICINE. <i>Rational Pharmacotherapy in Cardiology</i> , 2017 , 13, 69-70	0.5	3
25	PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2017 , 13, 416-421	0.5	2
24	CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2017 , 13, 771-775	0.5	
23	Urine metabolic ratio of omeprazole in relation to CYP2C19 polymorphisms in Russian peptic ulcer patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 253-259	2.1	7
22	Do and gene polymorphisms and low CYP3A4 isoenzyme activity have an impact on stent implantation complications in acute coronary syndrome patients?. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 243-245	2.1	3
21	Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration. <i>Drug Metabolism and Personalized Therapy</i> , 2017 , 32, 129-136	2	14
20	Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder. <i>Pharmacogenomics and Personalized Medicine</i> , 2017 , 10, 209-215	2.1	8
19	Pharmacogenetic evaluation of adverse events risk in patients with alcohol withdrawal syndrome taking bromdihydrochlorphenylbenzodiazepine: The role of CYP2C19 gene polymorphisms 2017 , 1, 18-26		1
18	Pharmacodynamic gene polymorphism and adverse drug reactions then applying antipsychotic drugs 2017 , 1, 5-12		1
17	Stages of development and implementation of personalized medicine technologies in clinical practice 2017 , 1, 1-4		1
16	The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. <i>Pharmacogenomics and Personalized Medicine</i> , 2016 , 9, 59-63	2.1	2
15	THE PHARMACOKINETICS OF APIXABAN IN PATIENTS WITH RADIOEMBOLIC STROKE IN ACUTE PHASE. <i>Rational Pharmacotherapy in Cardiology</i> , 2016 , 12, 253-259	0.5	1

14	The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction. <i>Pharmacogenomics and Personalized Medicine</i> , 2016 , 9, 89-95	2.1	16
13	1846G>A polymorphism of CYP2D6 gene and extrapyramidal side effects during antipsychotic therapy among Russians and Tatars: a pilot study. <i>Drug Metabolism and Personalized Therapy</i> , 2016 , 31, 205-212	2	6
12	The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation. <i>Drug Metabolism and Personalized Therapy</i> , 2016 , 31, 173-8	2	4
11	Clinical pharmacology in Russia-historical development and current state. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 159-63	2.8	8
10	Development of the ontology of patient management technological records for modeling of clinical workflows in a general hospital. <i>Scientific and Technical Information Processing</i> , 2015 , 42, 455-462 ^{0.8}		2
9	Decision support systems in clinical practice: The case of venous thromboembolism prevention. <i>International Journal of Risk and Safety in Medicine</i> , 2015 , 27 Suppl 1, S104-5	1.6	8
8	The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. <i>Pharmacogenomics and Personalized Medicine</i> , 2015 , 8, 111-4	2.1	9
7	GENETICS OF CLOPIDOGREL RESISTANCE: RECENT DATA. <i>Russian Journal of Cardiology</i> , 2015 , 92	1.3	2
6	EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2015 , 11, 85-91	0.5	7
5	APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY. <i>Rational Pharmacotherapy in Cardiology</i> , 2013 , 9, 698-700	0.5	4
4	THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE. <i>Rational Pharmacotherapy in Cardiology</i> , 2013 , 9, 404-408	0.5	2
3	Importance of the Pharmacokinetics of Valproic Acid in an Individualized Approach to the Treatment of Epileptic Women of Fertile Age. <i>Neuroscience and Behavioral Physiology</i> , 2012 , 42, 963-968 ^{0.3}		1
2	A case of hepatic injury suspected to be caused by Canephron N, a Centaurium Hill containing phytotherapeutics. <i>International Journal of Risk and Safety in Medicine</i> , 2011 , 23, 5-6	1.6	3
1	Pheno- and genotyping the prescription of drugs metabolized by CYP2D6. <i>Bulletin of Experimental Biology and Medicine</i> , 2002 , 134, 159-60	0.8	2